Chemed Reports Third-Quarter 2026 Results

Chemed reported Q3 2026 revenue of $690.9 million, up 10.6%, with GAAP diluted EPS up 22.2% to $5.45 and adjusted diluted EPS up 28.1% to $6.75. VITAS revenue rose 12.2% to $457.4 million, while adjusted EBITDA excluding Medicare Cap increased 31.4% to $92.5 million and its margin expanded 318 basis points to 20.2%. Roto-Rooter revenue increased 7.5% to $233.5 million, but net income fell 1.8% and adjusted EBITDA declined 2.5%.

Analysis

The result suggests a widening gap between Chemed’s two earnings engines: VITAS is generating operating leverage, while Roto-Rooter’s revenue growth is not converting into profit. That mix shift can support near-term earnings revisions, but it also makes CHE more exposed to hospice reimbursement, labor availability and Medicare-cap outcomes—and less insulated by the plumbing business. The key quality check is whether VITAS’s margin improvement persists after labor and other costs, and whether Medicare-cap effects excluded from the segment measure create a later earnings or cash-flow drag. Roto-Rooter’s margin decline is a watch item: if it reflects temporary labor or job mix, recovery could broaden growth; if pricing is failing to cover costs, consolidated growth will rely increasingly on VITAS. The release alone does not establish an earnings “beat” or attractive valuation; consensus, the call commentary and the stock’s reaction are needed. Over the next 1–3 months, watch VITAS admissions/census and cap exposure alongside Roto-Rooter margins. Over 6–18 months, persistent hospice strength could be offset by reimbursement changes or renewed cost pressure. A reversal in VITAS margin/census trends, or continued Roto-Rooter margin erosion, would falsify the constructive operating thesis.

Key Decisions for Investors

• Do not chase CHE solely on the reported growth rates. After the earnings call, consider a modest long only if management supports continued VITAS margin durability and clarifies Medicare-cap exposure; without valuation and consensus data, risk/reward is not yet compelling enough for an unconditional entry.
• For the next quarter, track VITAS admissions and average daily census against segment margins, and ask whether the reported improvement excluding Medicare Cap translates into cash earnings after cap effects. A slowdown in census or reversal in margins is a thesis exit signal.
• Treat Roto-Rooter as the near-term operating risk: monitor whether pricing and revenue mix recover its margin. Another quarter of declining margin despite revenue growth would argue against paying for consolidated growth and could offset VITAS-driven estimate upgrades.
• Before sizing a position, verify consensus revisions, valuation, cash conversion and management’s explanation of discrete items; the gap between GAAP and adjusted EPS makes the quality and persistence of adjusted earnings especially relevant.